Table 2.

Anthropomorphic Measurements

Variable	Treatment group			Estimated treatment effect (90 % C.I.)a
	LLLT (N = 15) ± SD	Lorcaserin (N = 14) ± SD	Combination (N = 15b) ± SD	Combination vs. LLLT only	Combination vs. Lorcaserin only
Weight, kg
Baseline	96.0 ± 15.3	94.4 ± 16.2	90.3 ± 14.0
Week 12	95.0 ± 14.2	90.7 ± 17.4	86.7 ± 14.2	−2.6 (-5.0, -0.3)	+0.1 (-2.3, +2.5)
Delta	−1.0 ± 4.4	−3.7 ± 3.3c	−3.5 ± 3.6c	P = .070	P = .950
Weight loss of >5 %, n (%)	2 (13)	8 (57)	5 (33)
Body Mass Index, kg/m2
Baseline	33.5 ± 3.9	33.6 ± 5.1	33.4 ± 4.2
Week 12	33.1 ± 3.5	32.3 ± 5.7	32.1 ± 4.3	−1.0 (-1.8, -0.1)	+0.0 (-0.8, +0.9)
Delta	−0.4 ± 1.5	−1.3 ± 1.2c	−1.3 ± 1.3c	P = .063	P = .973
Waist Circumference, cm
Baseline	105.3 ± 11.6	108.0 ± 15.7	100.9 ± 10.0
Week 12	103.0 ± 11.3	102.0 ± 16.3	96.9 ± 12.4	−1.8 (-5.4, +1.7)	+1.7 (-1.9, +5.4)
Delta	−2.3 ± 4.1d	−6.0 ± 7.3c	−4.0 ± 5.5d	P = .398	P = .436
Hip Circumference, cm
Baseline	119.1 ± 8.8	120.7 ± 12.1	119.0 ± 8.8
Week 12	118.1 ± 8.3	116.2 ± 12.0	116.0 ± 9.3	−2.0 (-3.6, -0.3)	+1.5 (-0.2, +3.2)
Delta	−1.0 ± 3.1	−4.5 ± 2.1e	−3.0 ± 3.0c	P = .059	P = .159
Waist-to-Hip ratio
Baseline	0.885 ± 0.086	0.892 ± 0.072	0.850 ± 0.063
Week 12	0.874 ± 0.086	0.874 ± 0.087	0.834 ± 0.068	−0.007 (-0.032, +0.018)	−0.001 (-0.027, +0.025)
Delta	−0.011 ± 0.035	−0.017 ± 0.053	−0.016 ± 0.032	P = .657	P = .961

CI Confidence Interval, SD Standard Deviation

^aEstimated treatment effect from analysis of covariance (ANCOVA) with the baseline value of the given variable included as a covariate

^bThere were 2 subjects in the combination group who discontinued prior to week 12 (one after week 2 and one after week 6). For these 2 subjects the last value of each variable was carried forward to week 12

^c p < 0.01 for paired t-test comparing week 12 versus baseline

^d p < 0.05 for paired t-test comparing week 12 versus baseline

^e p < 0.001 for paired t-test comparing week 12 versus baseline